Insulin Pumps: For Whom, When, Why?

  • Charles M. Peterson
  • Lois Jovanovic
Part of the Developments in Nephrology book series (DINE, volume 9)


In view of increasing knowledge of the function of the normal human pancreas, it is not surprising that there are now an increasing number of technical innovations that attempt to mimic pancreatic endocrine function. The normal pancreas secretes insulin constantly at a rate based on the metabolic needs of the individual. The basal rate of insulin secretion is relatively constant and comprises about one-half the total 24-hour insulin output, or about 0.3 units/kg/24 hours in the normal individual who is within 80–120% ideal body weight. The normal pancreas also senses blood glucose continuously and gives insulin or initiates counterregulatory activity depending on the absolute value of blood glucose and the rate of change of blood glucose. In addition, through neural input, the pancreas can anticipate ingestion of calories with insulin secretion so that the liver is “primed” to metabolize caloric intake. Finally, insulin is secreted in response to food based not only on the caloric and carbohydrate intake but also on the blood glucose at the moment of eating. Such a system is known as a “closed loop system” since it has the capability to sense glucose and respond appropriately. An open loop system provides only one limb of a closed loop system—either sensing glucose or infusing glucose.


Closed Loop System Glucose Sensor Continuous Subcutaneous Insulin Infusion Insulin Pump Normal Pancreas 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Selected Bibliography

  1. 1.
    Brunetti P, Alberti K, Albisser M, Hepp KD, Massi Beneditti M (eds). Artificial systems for insulin delivery. New York: Raven Press, 1982.Google Scholar
  2. 2.
    Clark L Jr, Duggan C. Implanted electroenzymatic glucose sensors. Diabetes Care 5: 174–180, 1982.PubMedCrossRefGoogle Scholar
  3. 3.
    Peterson CM. Diabetes management in the 80’s: the role of home blood glucose monitoring and new insulin delivery systems. New York: Praeger, 1982.Google Scholar
  4. 4.
    Rizza R, Gerich J, Haymond M, Westland R, Hall L, Clemens A, Service FJ. Control of blood sugar in insulin-dependent diabetes: comparisons of an artificial endocrine pancreas, continuous subcutaneous insulin infusion, and intensified conventional insulin therapy. N Engl J Med 303: 1313–1318, 1980.PubMedCrossRefGoogle Scholar
  5. 5.
    Santiago J, Clemens A, Clarke, W, Kipnis D. Closed-loop and open-loop devices for blood glucose control in normal and diabetic subjects. Diabetes 28: 71–81, 1979.PubMedGoogle Scholar
  6. 6.
    Schade D, Eaton R, Edwards W, Doberneck R, Spencer W, Carlson G, Bair R, Love J, Urenda R, Gaona J Jr. A remotely programmable insulin delivery system. Successful short-term implantation in man. J Am Med Assoc 247: 1848–1853, 1982.CrossRefGoogle Scholar
  7. 7.
    Schade DS, Santiago JV, Skyler JS, Rizza RA. Intensive insulin therapy. Princeton: Excerpta Medica, 1983.Google Scholar
  8. 8.
    Chanoch L, Jovanovic L, Peterson CM. Hand held computer programs to assist patients with type I diabetes to make insulin delivery decisions. Presented at the International Diabetes Educator Meeting, Australia, 1984.Google Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1986

Authors and Affiliations

  • Charles M. Peterson
  • Lois Jovanovic

There are no affiliations available

Personalised recommendations